Improvement of pleasure loss symptoms in obese patients treated with tirzepatide: A report on three cases

High-dose tirzepatide may be associated with neurobehavioral effects such as reduced motivation and anhedonia-like symptoms.

• Glucagon-like peptide-1 receptor agonists (GLP1RAs) are effective in treating obesity and metabolic diseases.
• Emerging evidence indicates that these drugs might influence reward-processing pathways and motivated behaviors.
• Some patients report experiencing diminished food cravings and addictive behaviors while on these therapies.
• There are anecdotal reports of reduced motivation and anhedonia-like symptoms in certain patients receiving high doses of tirzepatide.
• Clinical management strategies for these neurobehavioral effects are explored in this case series.

Simplified